<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126349">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457573</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 0711-0124</org_study_id>
    <nct_id>NCT01457573</nct_id>
  </id_info>
  <brief_title>Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms</brief_title>
  <acronym>LUTS</acronym>
  <official_title>Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20
      men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at
      baseline, 1, 2, and 3 months for urinary NGF, urine creatinine, NGF/CR ratio and patient
      reported outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NGF and NGF/Cr ratio-change</measure>
    <time_frame>From baseline to week 12 (3 months)</time_frame>
    <description>Urinary Nerve Growth Factor (NGF) and NGF/Cr ratio-change from baseline to week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>Baseline to weeks 4 and 8.</time_frame>
    <description>International Prostate Symptom Score, Patient Perception of Urgency Score (PPIUS), Perception of Bladder Condition (PBC), International Consultation on Incontinence Modular Questionnaire for male LUTS (ICIQ-MLUTS) and the International Consultation on Incontinence Modular Questionnaire LUTS Quality of Life (ICIQ-LUTSqol).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Tamsulosin 0.4 mg + Solifenacin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg and Solifenacin (Vesicare) 5 mg orally at the same time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin (Vesicare) 5 mg orally at the same time.</intervention_name>
    <description>Drug: Tamsulosin 0.4 mg in combination with Solifenacin 5 mg
All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg and Solifenacin (Vesicare) 5 mg orally at the same time.</description>
    <arm_group_label>Tamsulosin 0.4 mg + Solifenacin 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men &gt; 50 years old with symptomatic LUTS (clinical BPH)

          -  IPSS &gt; 8

          -  PSA &lt; 10 (negative biopsies within 6 months for any age-specific PSA elevation
             suspicious for prostate carcinoma)

          -  Post void residual urine &lt; 150 mls

          -  Urinary Flow rate &gt; 15 mL/sec

        Exclusion Criteria:

          -  Neurogenic bladder

          -  Urinary tract infection, Urinary stone(s), Urinary tract tumor

          -  Radiation therapy for urologic malignancy or prostate surgery; radiation to pelvic,
             colon, rectum, prostate, bladder, uterus or ovaries

          -  Alpha blocker therapy or anticholinergic therapy within 3 months of entry or 5 alpha
             reductase therapy within 18 months.

          -  History of cataracts with planned surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Boone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Methodist Hospital System</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 16, 2014</lastchanged_date>
  <firstreceived_date>October 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
